Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Analysts

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has earned an average recommendation of “Moderate Buy” from the eleven research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $40.80.

A number of brokerages recently weighed in on GMAB. Wall Street Zen lowered shares of Genmab A/S from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 18th. Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a research report on Wednesday, October 8th. Truist Financial boosted their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, July 8th. Guggenheim raised shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target on the stock in a research report on Tuesday, September 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Genmab A/S in a research report on Wednesday, October 15th.

Genmab A/S Trading Down 0.7%

Shares of NASDAQ GMAB opened at $29.92 on Thursday. The firm has a market cap of $19.21 billion, a PE ratio of 15.04, a PEG ratio of 1.68 and a beta of 0.98. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $33.65. The company has a fifty day moving average price of $28.45 and a 200 day moving average price of $23.56.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. Equities research analysts forecast that Genmab A/S will post 1.45 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently modified their holdings of GMAB. GAMMA Investing LLC raised its holdings in shares of Genmab A/S by 1,465.3% in the 1st quarter. GAMMA Investing LLC now owns 33,482 shares of the company’s stock valued at $656,000 after purchasing an additional 31,343 shares during the period. QRG Capital Management Inc. raised its holdings in shares of Genmab A/S by 213.7% in the 1st quarter. QRG Capital Management Inc. now owns 74,847 shares of the company’s stock valued at $1,465,000 after purchasing an additional 50,990 shares during the period. Blue Trust Inc. raised its holdings in shares of Genmab A/S by 169.9% in the 1st quarter. Blue Trust Inc. now owns 7,413 shares of the company’s stock valued at $145,000 after purchasing an additional 4,666 shares during the period. Oppenheimer Asset Management Inc. raised its holdings in shares of Genmab A/S by 20.5% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 249,468 shares of the company’s stock valued at $4,885,000 after purchasing an additional 42,361 shares during the period. Finally, DAVENPORT & Co LLC raised its holdings in shares of Genmab A/S by 21.1% in the 1st quarter. DAVENPORT & Co LLC now owns 31,679 shares of the company’s stock valued at $620,000 after purchasing an additional 5,529 shares during the period. 7.07% of the stock is owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.